ELVN MEXC RealStocks
Own real ELVN shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 17:03:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Enliven Therapeutics, Inc. (ELVN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $45.61, with a market capitalization of $3.45B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $14.79 to $62.32. This page covers its latest market performance, valuation, price trends and company information.
$3.45B | |
$45.17 | |
$46.27 | |
$44.74 | |
$44.89 | |
232.62K | |
1.36M | |
-- | |
$62.32 | |
$14.79 | |
-- | |
2026-09-30 |
Enliven Therapeutics, Inc. (ELVN) is currently trading at $45.61 as of 2026-11-19 17:01:00, up 2.38% ($1.07) from the previous close of $44.89
During today's regular trading session, ELVN has traded between $44.74 and $46.27, with a trading volume of 232.62K shares. The current price is near the middle of today's range.
Over the past seven days, Enliven Therapeutics, Inc. (ELVN) moved from $51.20 to $45.61, representing a decline of 10.93% ($5.60).
The stock traded between $44.72 and $52.23 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 816.72 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 64.8%
ELVN is currently trading at $45.61, placing it 64.8% of the way from its 52-week low of $14.79 to its 52-week high of $62.32. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 65 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Enliven Therapeutics, Inc. (ELVN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ELVN, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ELVN shares and USD.
ELVN Shares to USD
1.00 ELVN shares = 45.605 USD
Calculations are estimates based on the latest available price and are for reference only.